<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150969</url>
  </required_header>
  <id_info>
    <org_study_id>CIHR-50422</org_study_id>
    <nct_id>NCT00150969</nct_id>
  </id_info>
  <brief_title>Vitamin K Supplementation in Post-Menopausal Osteopenia</brief_title>
  <official_title>Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether supplementation with 5 mg vitamin K daily
      over a 2-year period will prevent bone loss in post-menopausal women with osteopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is major cause of morbidity and mortality in Canadian postmenopausal women. It
      is a systemic disease characterized by low bone mass and deterioration of bone
      microarchitecture, resulting in bone fragility and an increased risk of fractures. One in six
      women over the age of 50 have osteoporosis. The lifetime risk of an osteoporotic fracture for
      an average 50 year-old Canadian woman is &gt;40%. The annual health care costs for osteoporotic
      fractures in Canada have been estimated to exceed $1.3 billion.

      Recent data suggest that vitamin K supplements may decrease bone loss and prevent fractures.
      Vitamin K is a co-factor of gamma-glutamyl carboxylase, an enzyme that catalyzes the
      gamma-carboxylation of glutamic acid residues in bone matrix proteins such as osteocalcin.
      Vitamin K has been reported to enhance bone formation in both in vitro studies and in vivo
      studies in animals. Vitamin K levels are low in individuals with osteoporosis and in patients
      with osteoporotic fractures. The few studies examining vitamin K supplementation in humans
      have showed promising results with no significant side effects, but these studies had
      significant methodological shortcomings such as inadequate sample size and lack of
      randomization.

      The primary objective of our study is to examine whether vitamin K supplementation will
      increase bone mineral density in postmenopausal women with osteopenia. Our secondary
      objectives are to examine the possible adverse effects from long-term vitamin K
      supplementation, to investigate whether vitamin K will decrease risk of fractures and to
      determine if vitamin K affects quality of life. Our hypotheses are that vitamin K increases
      bone mineral density in postmenopausal women, and that there are no significant adverse
      effects from vitamin K supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker</measure>
    <time_frame>0-24 months</time_frame>
    <description>measured by osteocalcin on elecsys platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)</measure>
    <time_frame>0-24 months</time_frame>
    <description>measured by CTX Elisa assay on elecsys platform</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin</measure>
    <time_frame>0 to 24 months</time_frame>
    <description>measured by osteocalcin hydroxyapatite binding assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.</measure>
    <time_frame>0 to 48 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.</measure>
    <time_frame>0 to 48 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.</measure>
    <time_frame>0 to 48 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.</measure>
    <time_frame>0 to 48 months</time_frame>
    <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Serious Adverse Events</measure>
    <time_frame>up to 48 months</time_frame>
    <description>These include hospitalizations for pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgery, cancer and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Number of New Cancers by Treatment Arm.</measure>
    <time_frame>up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Number of New Clinical Fractures by Treatment Arm.</measure>
    <time_frame>up to 48 months</time_frame>
    <description>these included fragility fractures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">440</enrollment>
  <condition>Post-Menopausal Osteoporosis</condition>
  <condition>Post-Menopausal Osteopenia</condition>
  <arm_group>
    <arm_group_label>phyloquinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg Vitamin K1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin K1 (phylloquinone)</intervention_name>
    <arm_group_label>phyloquinone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 pill daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Postmenopausal: One year since the natural cessation of menses, or Hysterectomy with either
        postmenopausal status confirmed by FSH lab values, or age 55 and above AND 2. Osteopenic:
        T-score at baseline has to be between (and including) -1.0 and

        -2.0 in the lumbar spine (L1-L4), total hip or femoral neck, and the lowest reading of the
        above three measurements must be between -1.0 and -2.0

        Exclusion Criteria:

          1. Women ever having had a fragility fracture after age 40;

          2. Women currently on anticoagulants, previously on anticoagulants in the past 3 months,
             or expected to be on anticoagulants in the near future;

          3. Women on hormone replacement therapy, raloxifene, bisphosphonates or calcitonin during
             the past 3 months;

          4. Women who have ever been on a bisphosphonate for more than 6 months;

          5. Women previously diagnosed with Paget's disease, hyperparathyroidism, hyperthyroidism
             or other metabolic bone diseases;

          6. Women with decompensated diseases of the liver, kidney, pancreas, lung, or heart;

          7. Women with a history of active cancer in the past 5 years;

          8. Women taking mega-doses of vitamin A (more than 10,000 iu per day) or E (more than 400
             iu per day);

          9. Women involved in other clinical trials;

         10. Any women who, in the opinion of the principal investigator, is at poor medical or
             psychiatric risk for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela M Cheung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michael's Hospital Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Osteoporosis Department</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook &amp; Women's College Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med. 2008 Oct 14;5(10):e196. doi: 10.1371/journal.pmed.0050196. Erratum in: PLoS Med. 2008 Dec;5(12):e247.</citation>
    <PMID>18922041</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>January 10, 2012</results_first_submitted>
  <results_first_submitted_qc>February 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2012</results_first_posted>
  <last_update_submitted>November 19, 2012</last_update_submitted>
  <last_update_submitted_qc>November 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <keyword>vitamin K</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>post-menopausal women</keyword>
  <keyword>randomized double blind placebo controlled trial</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>women's health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment from January 2002 to September 2006 through health fairs, community posters and advertisements.</recruitment_details>
      <pre_assignment_details>453 participants signed consent. 13 were not included in analysis(10 screen failure,3 drop out at baseline)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phyloquinone</title>
          <description>5 mg Vitamin K1</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>dummy pill identicle to vitamin k</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>24 Month Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24-48 Month Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phyloquinone</title>
          <description>5 mg Vitamin K1</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>dummy pill identicle to vitamin k</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="440"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" lower_limit="40.1" upper_limit="80.5"/>
                    <measurement group_id="B2" value="59.2" lower_limit="46.1" upper_limit="82.3"/>
                    <measurement group_id="B3" value="59.0" lower_limit="40.1" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>All Participants were community dwelling post-menopausal women</description>
          <units>participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 24 months</time_frame>
        <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="3.5" lower_limit="-0.67" upper_limit="0.54"/>
                    <measurement group_id="O2" value="-1.22" spread="3.0" lower_limit="-0.67" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 24 months</time_frame>
        <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="3.7"/>
                    <measurement group_id="O2" value="-1.83" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 24 months</time_frame>
        <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="4.0"/>
                    <measurement group_id="O2" value="-2.55" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker</title>
        <description>measured by osteocalcin on elecsys platform</description>
        <time_frame>0-24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Vitamin K1 Supplementation on Levels of Bone Formation Marker</title>
          <description>measured by osteocalcin on elecsys platform</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="7.3"/>
                    <measurement group_id="O2" value="24" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)</title>
        <description>measured by CTX Elisa assay on elecsys platform</description>
        <time_frame>0-24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Vitamin K1 Supplementation on Level of Bone Resorption Markers (C-telopeptide: CTX)</title>
          <description>measured by CTX Elisa assay on elecsys platform</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.21"/>
                    <measurement group_id="O2" value="0.54" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin</title>
        <description>measured by osteocalcin hydroxyapatite binding assay</description>
        <time_frame>0 to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Vitamin K1 Supplementation on Percent of Carboxylation of Osteocalcin</title>
          <description>measured by osteocalcin hydroxyapatite binding assay</description>
          <units>percentage of undercarboxylated OC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" spread="10.3"/>
                    <measurement group_id="O2" value="-2.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="3.6"/>
                    <measurement group_id="O2" value="-1.52" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 24 months</time_frame>
        <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Total Hip Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <population>For our 2 year BMD anlayses we included all 440 women based on intention to treat using last observation carried forward for missing data.</population>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="2.8" lower_limit="-0.37" upper_limit="0.75"/>
                    <measurement group_id="O2" value="-0.88" spread="3.2" lower_limit="-0.37" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine (L1-L4) Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="4.7"/>
                    <measurement group_id="O2" value="-1.76" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Femoral Neck Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" spread="4.3"/>
                    <measurement group_id="O2" value="-2.71" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.</title>
        <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
        <time_frame>0 to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Bone Mineral Density (BMD) at the Ultra-distal Radius Between Treatment Arms.</title>
          <description>BMD was measured yearly on one scanner at UHN using DEXA Hologic 4500A densitometer</description>
          <units>percentage change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.35" spread="5.1"/>
                    <measurement group_id="O2" value="-5.23" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Serious Adverse Events</title>
        <description>These include hospitalizations for pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgery, cancer and death.</description>
        <time_frame>up to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Serious Adverse Events</title>
          <description>These include hospitalizations for pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgery, cancer and death.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Number of New Cancers by Treatment Arm.</title>
        <time_frame>up to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of New Cancers by Treatment Arm.</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Number of New Clinical Fractures by Treatment Arm.</title>
        <description>these included fragility fractures</description>
        <time_frame>up to 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phyloquinone</title>
            <description>5 mg Vitamin K1 daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>dummy pill identicle to vitamin k</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Number of New Clinical Fractures by Treatment Arm.</title>
          <description>these included fragility fractures</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the entire study period of 48 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phyloquinone</title>
          <description>5 mg Vitamin K1</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>dummy pill identicle to vitamin k</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>these include pneumonia, heart failure, gastro-intestinal bleeding, elective and non-elective surgeries.</description>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <description>cancers include uterine (2), vaginal(1), esophagus(1), thyroid(3), breast(7), lung (1)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Causes of death include motor vehicle accident (1), arrhthmogenic right ventricular cardiomyopathy(1) cancer(3),</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>ICD-9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomitting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Originally designed as a 2-year study with BMD as primary outcome. Thus, the number of women followed to 3 and 4 years was small, and the study was not powered to examine fracture outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Angela M Cheung</name_or_title>
      <organization>University Health Network</organization>
      <phone>416-340-4841</phone>
      <email>jscher@uhnresearch.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

